Managing type 2 diabetes patients with heart and kidney risks: Comparing European and American guidelines
Updated
Abstract
Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors are now preferred treatments for type 2 diabetes patients at cardiovascular risk.
- These medications provide cardiovascular and renal protection beyond their effects on blood sugar levels.
- Recent guidelines from the European Society of Cardiology and the ADA-EASD highlight their importance in managing cardiovascular risk.
- Discrepancies exist in the definitions of cardiovascular risk patients, particularly in primary prevention contexts.
- Metformin remains the first-choice treatment for many patients despite the emerging role of these newer medications.
Simplified
Funding
Competing interests
A. J. Scheen déclare avoir reçu des honoraires comme orateur, membre d’un conseil scientifique ou investigateur clinicien de la part des firmes AstraZeneca, Boehringer Ingelheim, Janssen, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi et Servier. Il a été investigateur clinicien dans les études EMPA-REG OUTCOME, CANVAS-R, DECLARE-TIMI 58, LEADER et HARMONY OUTCOME.N. Paquot déclare avoir reçu des honoraires comme orateur, membre d’un conseil scientifique ou investigateur clinicien de la part des firmes AstraZeneca, Boehringer Ingelheim et Eli Lilly.
PubMed